Evasc Neurovascular Enterprises

Name

Evasc Neurovascular Enterprises

Legal name

Evasc Medical Systems Corp.

Website

https://evasc.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Cerebral aneurysm treatment
• Endovascular medical devices
• Neurovascular implants
• Nitinol clip devices
• Bifurcation aneurysm repair

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Evasc generates revenue through the sale of its eCLIPs endovascular devices to hospitals and neurointerventional centers. The company sells multiple generations of devices (eBRS, eB, eBFD) and associated delivery systems. Revenue is generated on a per-procedure basis as devices are used in aneurysm treatments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Evasc designs, develops, and manufactures the eCLIPs family of nitinol-based endovascular implant devices used to treat cerebral aneurysms, particularly wide-neck bifurcation aneurysms. The devices bridge the aneurysm neck from outside the sac using a proprietary spine-rib architecture that delivers flow diversion, coil retention, and endothelial scaffolding. The product line spans three generations—eBRS, eB (Electrolytic Bifurcation System), and eBFD (Bifurcation Flow Diverter)—sold to hospitals and neurointerventional centers across Europe.

Product overview

Evasc Neurovascular Enterprises offers the eCLIPs platform, a family of medical devices designed for endovascular treatment of cerebral aneurysms, particularly wide-neck bifurcations. The portfolio includes three generations of the eCLIPs Bifurcation System: the original eBRS (Bifurcation Aneurysm Remodeling System), the second-generation eB with electrolytic detachment and improved deliverability, and the third-generation eBFD (Bifurcation Flow Diverter) with higher metal coverage for flow diversion. The eCLIPs system is designed to treat 95% of cerebral aneurysms and operates by bridging the aneurysm neck, creating flow diversion effect, and providing scaffolding for endothelial growth. The system includes the implant, delivery wire, and sheath components.

Differentiator

Problem solved

Functional benefit

Brands

• eCLIPs: Endovascular clip system for treatment of wide-neck bifurcation aneurysms. Includes eB (Bifurcation Remodeling System), eBRS (Bifurcation Aneurysm Remodeling System), and eBFD (Bifurcation Flow Diverter) variants.

Products and services

• eCLIPs Bifurcation Aneurysm Remodeling System (eBRS) First-generation nitinol endovascular device of the eCLIPs platform used by neurointerventional physicians in hospitals and neurointerventional centers to treat wide-neck bifurcation aneurysms through neck bridging, flow diversion effect, and scaffolding to enable endothelial growth while supporting embolic coils.
• eCLIPs Electrolytic Bifurcation System (eB) Second-generation eCLIPs device with electrolytic detachment and improved delivery system featuring a torquable wire. Compatible with standard 021 and 027 microcatheters and bridges necks up to 12mm. Supports embolic coils with ancillary flow-diverting effect. Sold to hospitals in CE Mark regions (notably the European Union including France).
• eCLIPs Bifurcation Flow Diverter (eBFD) Third-generation eCLIPs with 35% leaf density (60% higher than prior generations), achieving aneurysm occlusion through flow diversion alone without requiring coiling. Covers neck lengths up to 6mm and offers simplified deployment with reduced delivery times for neurointerventional physicians and hospitals.
• eCLIPs 0.021" Microcatheter Compatible Flow Diverter (eBFD) Limited commercial release flow diverter specifically engineered for short landing zone anatomies, particularly middle cerebral artery (MCA) and anterior communicating artery (ACom) bifurcations. Features 35% leaf density, compatibility with 0.021" catheters, coverage for neck lengths up to 5mm, and streamlined delivery in under 10 minutes. Targeted at high-volume academic neurointerventional centers globally.

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MicroVention (Terumo): MicroVention, a Terumo subsidiary, is a leading neurovascular device company with overlapping aneurysm franchises including the WEB intrasaccular device and flow diverters — directly competitive with eCLIPs in wide-neck bifurcation aneurysm treatment.
• phenox: phenox is a privately held German neurovascular device specialist focused on aneurysm and stroke treatment devices (including p64 and p48 flow diverters). Comparable as a smaller, focused competitor in the niche bifurcation/flow diversion space where Evasc operates.

Broad incumbents

• Medtronic Neurovascular: Medtronic's neurovascular portfolio (Pipeline embolization device family) competes directly with Evasc in flow diversion for aneurysms; medtech giant with deep neurovascular salesforce and global footprint including the US market where Evasc is not yet approved.
• Stryker Neurovascular: Stryker's neurovascular division (Surpass flow diverter, Target coils) competes directly in the aneurysm treatment space. Its broad portfolio and global neurovascular channel present a powerful incumbent competitor to eCLIPs.
• Penumbra: Penumbra is a neurovascular and peripheral vascular device company developing aneurysm treatment technologies (including coil systems) — a relevant incumbent competitor with global commercialization capabilities.
• Cerenovus (Johnson & Johnson MedTech): Cerenovus, J&J MedTech's neurovascular business, offers a portfolio that overlaps with aneurysm treatment (embolic coils, flow diverters, access devices), making it a broad incumbent competitor with strong US channel presence.
• Stryker (acquired Sequent Medical / WEB): Sequent Medical was acquired by Terumo (now MicroVention) for the WEB intrasaccular aneurysm device — a direct functional competitor to eCLIPs for bifurcation aneurysms; included to highlight the most direct competitive analog in product category.

Emerging players

• Rapid Medical: Rapid Medical is an emerging neurovascular company with adjustable stent technologies (Tigertriever, Comaneci) overlapping in the aneurysm/stroke intervention space where Evasc sells eCLIPs.
• MIVI Neuroscience: MIVI Neuroscience is a smaller neurovascular device company developing access and treatment technologies for ischemic stroke and aneurysm procedures — comparable as another emerging specialist in the same endovascular neurovascular space.
• InspireMD: InspireMD is a smaller medical device company developing neurovascular and carotid stent technologies (CGuard), overlapping with Evasc in endovascular neurovascular intervention, though primarily in carotid vs. cerebral applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/EvascMed
• LinkedInlinkedin.com/company/evasc-medical-systems

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evasc Neurovascular Enterprises